ClinConnect ClinConnect Logo
Search / Trial NCT00945100

Increasing Patching for Amblyopia in Children 3 to < 8 Years Old

Launched by JAEB CENTER FOR HEALTH RESEARCH · Jul 21, 2009

Trial Information

Current as of May 18, 2025

Completed

Keywords

Amblyopia Patching Occlusion

ClinConnect Summary

Amblyopia is the most common cause of monocular visual impairment in both children and young and middle-aged adults. Both patching and atropine are accepted treatment modalities for the management of moderate amblyopia in children.1 Many practitioners prescribe 2 hours daily patching as initial therapy for amblyopia. However, many children fail to achieve normal visual acuity in the amblyopic eye with this regimen. In a randomized trial conducted by PEDIG comparing patching regimens, 71 of 92 patients with moderate amblyopia (77%) had amblyopic eye visual acuity of 20/32 or worse after 4 mo...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Major Eligibility Criteria for Run-in Phase
  • Age 3 to \< 8 years
  • Amblyopia associated with strabismus, anisometropia, or both
  • Visual acuity in the amblyopic eye between 20/50 and 20/400 inclusive
  • Visual acuity in the sound eye 20/32 or better and inter-eye acuity difference \>3 logMAR lines
  • * Amblyopia treatment within the past 6 months subject to the following stipulations:
  • No more than 6 weeks of any amblyopia treatment other than spectacles (except for patients being treated with 2 hours of patching per day who are entering the study on treatment)
  • No simultaneous treatment with patching and atropine
  • No use of atropine in combination with the sound eye spectacle lens reduced by more than 1.50 D
  • * Maximum level of treatment within the past 6 months:
  • Patching: up to 2 hours daily
  • Atropine: up to once daily
  • Wearing spectacles with optimal correction (if applicable); if amblyopic eye acuity is 20/80 or better, then VA must be stable in glasses. If amblyopic eye acuity is 20/100 or worse, then spectacles and patching can be initiated simultaneously.
  • Eligibility Criteria for Randomization:
  • Amblyopic eye acuity of 20/40 to 20/160 with an inter-ocular difference of \>2 lines, or amblyopic eye acuity of 20/32 with 3 lines of IOD.
  • Reasonable compliance with prescribed treatment, defined as wearing the patch at least 10 hours per week.
  • Exclusion Criteria:
  • Currently using vision therapy or orthoptics
  • Ocular cause for reduced visual acuity (nystagmus per se does not exclude the patient if the above visual acuity criteria are met)
  • Prior intraocular or refractive surgery
  • Known skin reaction to patch or bandage adhesives

About Jaeb Center For Health Research

The Jaeb Center for Health Research is a leading nonprofit organization dedicated to advancing medical research through innovative clinical trials and data analysis. With a strong emphasis on improving patient outcomes, the Center collaborates with healthcare professionals and institutions to conduct rigorous studies across various therapeutic areas, particularly in ophthalmology and diabetes. By leveraging cutting-edge methodologies and a commitment to ethical research practices, the Jaeb Center strives to enhance the understanding of disease mechanisms and develop effective treatment options, ultimately contributing to the improvement of public health.

Locations

Fullerton, California, United States

Durham, North Carolina, United States

Patients applied

0 patients applied

Trial Officials

David K. Wallace, M.D.

Study Chair

Duke University Eye Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials